NASDAQ:FWBI First Wave BioPharma (FWBI) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free FWBI Stock Alerts $2.75 -0.27 (-8.94%) (As of 10:00 AM ET) Add Compare Share Share Today's Range$2.75▼$3.0150-Day Range$2.60▼$9.2452-Week Range$2.42▼$65.00Volume13,875 shsAverage Volume245,487 shsMarket Capitalization$5.58 millionP/E RatioN/ADividend YieldN/APrice Target$118.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get First Wave BioPharma alerts: Email Address First Wave BioPharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3,807.3% Upside$118.00 Price TargetShort InterestHealthy3.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$15,968 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.83 out of 5 stars 3.3 Analyst's Opinion Consensus RatingFirst Wave BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFirst Wave BioPharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.04% of the float of First Wave BioPharma has been sold short.Short Interest Ratio / Days to CoverFirst Wave BioPharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in First Wave BioPharma has recently increased by 295.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFirst Wave BioPharma does not currently pay a dividend.Dividend GrowthFirst Wave BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FWBI. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for First Wave BioPharma this week, compared to 1 article on an average week.MarketBeat Follows5 people have added First Wave BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, First Wave BioPharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,968.00 in company stock.Percentage Held by InsidersOnly 0.49% of the stock of First Wave BioPharma is held by insiders.Percentage Held by InstitutionsOnly 12.30% of the stock of First Wave BioPharma is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of First Wave BioPharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of First Wave BioPharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFirst Wave BioPharma has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About First Wave BioPharma Stock (NASDAQ:FWBI)First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Read More FWBI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FWBI Stock News HeadlinesApril 24, 2024 | globenewswire.comFirst Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsApril 17, 2024 | finance.yahoo.comFirst Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseApril 25, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 15, 2024 | globenewswire.comFirst Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceApril 5, 2024 | investing.comFirst wave BioPharma CEO sells shares to cover tax obligationsMarch 21, 2024 | investing.comFirst wave BioPharma CFO sells shares worth over $5,500March 21, 2024 | investing.comFirst wave BioPharma CEO sells shares worth over $9,000March 18, 2024 | globenewswire.comFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceApril 25, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 14, 2024 | investorplace.comWhy Is First Wave BioPharma (FWBI) Stock Up Today?March 14, 2024 | msn.comFirst Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac DiseaseMarch 14, 2024 | globenewswire.comFirst Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineMarch 5, 2024 | finance.yahoo.comFirst Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth ConferenceMarch 5, 2024 | globenewswire.comFirst Wave BioPharma to Participate In ‘Fireside Chat' at the 36th Annual Roth ConferenceMarch 4, 2024 | marketwatch.comFirst Wave BioPharma Shares Drop 25% After Direct Offering PricesMarch 4, 2024 | msn.comFirst Wave Biopharma to raise about $4M of proceeds in direct offeringMarch 4, 2024 | finance.yahoo.comFirst Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct OfferingFebruary 13, 2024 | finance.yahoo.comFirst Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024January 23, 2024 | finance.yahoo.comFirst Wave BioPharma to Present at the DealFlow MicroCap ConferenceJanuary 22, 2024 | benzinga.comThis BioPharma Could Be First To Market With Its Celiac Therapy – Phase 3 Clinical Trials To Commence In 2024January 8, 2024 | msn.comFirst Wave BioPharma files to sell 1.76M for holdersJanuary 6, 2024 | msn.comFirst Wave expecting "significant" investments if ImmunogenX deal closesJanuary 4, 2024 | finance.yahoo.comFirst Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024January 3, 2024 | msn.comWhat's Going On With First Wave BioPharma Stock?January 3, 2024 | realmoney.thestreet.comFirst Wave BioPharma price target set at $40 at Roth MKMJanuary 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for First Wave BioPharma Amid Strategic Focus on Celiac TreatmentDecember 27, 2023 | markets.businessinsider.comCrude Oil Falls Over 1%; First Wave BioPharma Shares Spike HigherSee More Headlines Receive FWBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FWBI CUSIPN/A CIK1604191 Webwww.azurrx.com Phone(561) 589-7020FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$118.00 High Stock Price Target$200.00 Low Stock Price Target$36.00 Potential Upside/Downside+3,807.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($272.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-603.03% Return on Assets-278.67% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book1.31Miscellaneous Outstanding Shares2,030,000Free Float2,015,000Market Cap$6.13 million OptionableNot Optionable Beta1.24 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. James R. Sapirstein M.B.A. (Age 63)R.Ph., CEO & Chairman Comp: $906.2kMs. Sarah Romano CPA (Age 43)Chief Financial Officer Comp: $624.88kDr. Jack A. Syage Ph.D. (Age 69)President, COO & Director Ms. Amy Chandler-Skerkis (Age 55)Vice President of Regulatory Affairs, QA & Compliance Mr. Martin Krusin M.B.A.Senior Vice President of Corporate DevelopmentKey CompetitorsAinosNASDAQ:AIMDKazia TherapeuticsNASDAQ:KZIAShuttle PharmaceuticalsNASDAQ:SHPHVaccinexNASDAQ:VCNXEnveric BiosciencesNASDAQ:ENVBView All CompetitorsInsidersJames SapirsteinSold 174 sharesTotal: $736.02 ($4.23/share)Sarah RomanoSold 75 sharesTotal: $317.25 ($4.23/share)James SapirsteinSold 1,887 sharesTotal: $9,359.52 ($4.96/share)Sarah RomanoSold 1,120 sharesTotal: $5,555.20 ($4.96/share)James SapirsteinSold 166 sharesTotal: $697.20 ($4.20/share)View All Insider Transactions FWBI Stock Analysis - Frequently Asked Questions Should I buy or sell First Wave BioPharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FWBI shares. View FWBI analyst ratings or view top-rated stocks. What is First Wave BioPharma's stock price target for 2024? 2 equities research analysts have issued 1 year price objectives for First Wave BioPharma's shares. Their FWBI share price targets range from $36.00 to $200.00. On average, they predict the company's share price to reach $118.00 in the next twelve months. This suggests a possible upside of 3,807.3% from the stock's current price. View analysts price targets for FWBI or view top-rated stocks among Wall Street analysts. How have FWBI shares performed in 2024? First Wave BioPharma's stock was trading at $4.20 on January 1st, 2024. Since then, FWBI stock has decreased by 28.1% and is now trading at $3.02. View the best growth stocks for 2024 here. Are investors shorting First Wave BioPharma? First Wave BioPharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 55,000 shares, an increase of 295.7% from the March 15th total of 13,900 shares. Based on an average trading volume of 140,300 shares, the days-to-cover ratio is currently 0.4 days. Approximately 3.0% of the company's shares are short sold. View First Wave BioPharma's Short Interest. When is First Wave BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our FWBI earnings forecast. How were First Wave BioPharma's earnings last quarter? First Wave BioPharma, Inc. (NASDAQ:FWBI) issued its quarterly earnings results on Sunday, November, 14th. The company reported ($13,734.00) EPS for the quarter, missing analysts' consensus estimates of ($3,318.00) by $10,416.00. When did First Wave BioPharma's stock split? First Wave BioPharma's stock reverse split before market open on Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of First Wave BioPharma? Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FWBI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Wave BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
